| Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients A Cabre, I Lazaro, J Girona, JM Manzanares, F Marimon, N Plana, ... Atherosclerosis 195 (1), e150-e158, 2007 | 180 | 2007 |
| Retinol‐binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes A Cabre, I Lazaro, J Girona, J Manzanares, F Marimon, N Plana, M Heras, ... Journal of internal medicine 262 (4), 496-503, 2007 | 161 | 2007 |
| Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes A Cabré, I Lázaro, J Girona, JM Manzanares, F Marimón, N Plana, ... Journal of lipid research 49 (8), 1746-1751, 2008 | 128 | 2008 |
| Suppressor of cytokine signaling 1–derived peptide inhibits Janus Kinase/signal transducers and activators of transcription pathway and improves inflammation and … C Recio, A Oguiza, I Lazaro, B Mallavia, J Egido, C Gomez-Guerrero Arteriosclerosis, thrombosis, and vascular biology 34 (9), 1953-1960, 2014 | 80 | 2014 |
| Targeting HSP90 ameliorates nephropathy and atherosclerosis through suppression of NF-κB and STAT signaling pathways in diabetic mice I Lazaro, A Oguiza, C Recio, B Mallavia, J Madrigal-Matute, J Blanco, ... Diabetes 64 (10), 3600-3613, 2015 | 78 | 2015 |
| Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis B Mallavia, C Recio, A Oguiza, G Ortiz-Muñoz, I Lazaro, V Lopez-Parra, ... The American journal of pathology 182 (5), 1910-1921, 2013 | 76 | 2013 |
| Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes G Aragonès, R Ferré, I Lázaro, A Cabré, N Plana, J Merino, M Heras, ... Atherosclerosis 213 (1), 329-331, 2010 | 73 | 2010 |
| Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria A Cabre, I Lazaro, J Girona, JM Manzanares, F Marimon, N Plana, ... Clinical chemistry 54 (1), 181-187, 2008 | 69 | 2008 |
| Nrf2 activation provides atheroprotection in diabetic mice through concerted upregulation of antioxidant, anti-inflammatory, and autophagy mechanisms I Lazaro, L Lopez-Sanz, S Bernal, A Oguiza, C Recio, A Melgar, ... Frontiers in pharmacology 9, 819, 2018 | 67 | 2018 |
| Ellagic acid as a tool to limit the diabetes burden: Updated evidence AJ Amor, C Gómez-Guerrero, E Ortega, A Sala-Vila, I Lázaro Antioxidants 9 (12), 1226, 2020 | 64 | 2020 |
| SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition L Lopez-Sanz, S Bernal, C Recio, I Lazaro, A Oguiza, A Melgar, ... Laboratory investigation 98 (10), 1276-1290, 2018 | 55 | 2018 |
| Suppressor of cytokine signaling-1 peptidomimetic limits progression of diabetic nephropathy C Recio, I Lazaro, A Oguiza, L Lopez-Sanz, S Bernal, J Blanco, J Egido, ... Journal of the American Society of Nephrology 28 (2), 575-585, 2017 | 49 | 2017 |
| FABP4 plasma levels are increased in familial combined hyperlipidemia A Cabré, I Lázaro, M Cofán, E Jarauta, N Plana, AL Garcia-Otín, ... Journal of lipid research 51 (5), 1173-1178, 2010 | 49 | 2010 |
| Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 … N Peradze, OM Farr, N Perakakis, I Lázaro, A Sala-Vila, CS Mantzoros Cardiovascular diabetology 18, 1-12, 2019 | 47 | 2019 |
| The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients B Coll, A Cabre, C Alonso-Villaverde, I Lazaro, G Aragonés, S Parra, ... Atherosclerosis 199 (1), 147-153, 2008 | 47 | 2008 |
| Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes A Oguiza, C Recio, I Lazaro, B Mallavia, J Blanco, J Egido, ... Diabetologia 58, 1656-1667, 2015 | 45 | 2015 |
| Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice C Recio, A Oguiza, B Mallavia, I Lazaro, G Ortiz-Munoz, O Lopez-Franco, ... Basic research in cardiology 110, 1-11, 2015 | 45 | 2015 |
| APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome A Castro, I Lázaro, DM Selva, E Céspedes, J Girona, M Guardiola, ... Atherosclerosis 209 (1), 201-205, 2010 | 45 | 2010 |
| Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross‐over, randomized, double‐blind, controlled inpatient physiology study D Tuccinardi, OM Farr, J Upadhyay, SM Oussaada, MI Klapa, M Candela, ... Diabetes, Obesity and Metabolism 21 (9), 2086-2095, 2019 | 42 | 2019 |
| FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study A Cabré, N Babio, I Lázaro, M Bulló, A Garcia-Arellano, L Masana, ... Atherosclerosis 222 (1), 229-234, 2012 | 41 | 2012 |
